N-Acetyl Leucine Treats Niemann-Pick Disease Type C with NPC1 Mutations
Summary
The USPTO published patent application US20260097008A1 by inventor Michael Strupp covering methods of treating Niemann-Pick Disease Type C (NPC) or neurological symptoms thereof by administering N-acetyl leucine to subjects carrying NPC1 mutations. The application (No. 19352209) was filed October 7, 2025, and published April 9, 2026.
What changed
The USPTO published a patent application disclosing methods of treating Niemann-Pick Disease Type C (NPC) and associated neurological symptoms using N-acetyl leucine in patients harboring NPC1 gene mutations. The application claims therapeutic compositions and dosing regimens.
Affected parties including pharmaceutical companies, biotechnology firms, and research institutions developing NPC treatments should monitor this application for potential freedom-to-operate implications or licensing opportunities regarding N-acetyl leucine-based therapies for NPC patients with NPC1 mutations.
What to do next
- Monitor for patent grant or office action responses
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ACETYL LEUCINE FOR USE IN TREATING NIEMANN-PICK DISEASE TYPE C
Application US20260097008A1 Kind: A1 Apr 09, 2026
Inventors
Michael STRUPP
Abstract
The present disclosure provides methods of treating NPC, or a neurological symptom thereof, in a subject by administering a therapeutically effective amount of N-acetyl leucine, wherein the subject has one or more NPC1 mutations.
CPC Classifications
A61K 31/198 A61K 31/445 A61P 25/28
Filing Date
2025-10-07
Application No.
19352209
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.